Company Profile
CytomX Therapeutics, Inc. Stock Price, News & Analysis
- Ticker:
- CTMX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.37 USD (+0.60%)
Close
Last updated: August 6, 2026
688M USD
Market cap
Why the stock is moving
The latest monitored company update is “CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update.” The corresponding closing-price reaction is not yet available.
Company overview
Conditionally Activated Biologics
CytomX Therapeutics develops masked PROBODY therapeutics designed to become active in the tumor microenvironment. The approach aims to improve the therapeutic window of potent antibodies and antibody-drug conjugates.
Varsetatug Masetecan
Varsetatug masetecan, or Varseta-M, is an EpCAM-directed PROBODY antibody-drug conjugate in Phase 1 development. Its lead indication is advanced colorectal cancer, with dose optimization intended to support a potential registrational study.
Colorectal-Cancer Strategy
The Phase 1 dose-optimization program in advanced colorectal cancer is intended to select a monotherapy regimen and support a potential registrational study in the late-line setting.
Combination Development
CytomX is evaluating Varseta-M with bevacizumab and plans a separate chemotherapy-combination study to test whether partner agents can broaden or deepen activity.
Non-Colorectal Expansion
Additional Phase 1 cohorts will assess Varseta-M in non-colorectal EpCAM-expressing tumors, extending the program beyond its initial indication.
Future catalysts
Varseta-M dose-optimization data in the second half of 2026.
Initiation of a Phase 1/2 chemotherapy-combination study of Varseta-M in the second half of 2026.
Initiation of Phase 1 expansion cohorts in non-colorectal indications in the second half of 2026.
Initial data for Varseta-M plus bevacizumab by the first half of 2027.
Recent news
- 01
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
Source: CytomX Therapeutics, Inc.
- 02
CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer
Source: CytomX Therapeutics, Inc.
- 03
CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
Source: CytomX Therapeutics, Inc.
- 04
CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors
Source: CytomX Therapeutics, Inc.
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of CytomX Therapeutics, Inc. (CTMX)?
CytomX Therapeutics, Inc. (CTMX) most recently closed at 3.37 USD, a +0.60% move versus the previous session.
What is the market cap of CytomX Therapeutics, Inc. (CTMX)?
CytomX Therapeutics, Inc. currently has a market capitalization of 688M USD on BioPharmSignal.
What does CytomX Therapeutics, Inc. do?
Conditionally Activated Biologics CytomX Therapeutics develops masked PROBODY therapeutics designed to become active in the tumor microenvironment. The approach aims to improve the therapeutic window of potent antibodies and antibody-drug conjugates. Varsetatug Masetecan Varsetatug masetecan, or Varseta-M, is an EpCAM-directed PROBODY antibody-drug...
On which exchange is CTMX stock listed?
CytomX Therapeutics, Inc. (CTMX) is associated with NASDAQ, United States, Biopharma.
What is bevacizumab?
Initial data for Varseta-M plus bevacizumab by the first half of 2027.
Which conditions is CytomX Therapeutics, Inc. targeting with bevacizumab?
CytomX Therapeutics, Inc. is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does CytomX Therapeutics, Inc. describe recent progress with bevacizumab?
Initial data for Varseta-M plus bevacizumab by the first half of 2027.
What is Conditionally?
Conditionally Activated Biologics CytomX Therapeutics develops masked PROBODY therapeutics designed to become active in the tumor microenvironment.